{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:43:22Z","timestamp":1740185002342,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00347-023-01936-z","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T15:02:24Z","timestamp":1699369344000},"page":"152-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bilaterale Myelin-Oligodendrozyten-Glykoprotein (MOG)-Antik\u00f6rper-assoziierte Optikusneuritis","Bilateral Myelin oligodendrocyte glycoprotein (MOG)antibody-associated optic nerve neuritis"],"prefix":"10.1007","volume":"121","author":[{"given":"Julian","family":"Bucur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klemens Paul","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin Lucas","family":"Biller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyll","family":"Jandewerth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ninel","family":"Kenikstul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6933-9585","authenticated-orcid":false,"given":"Thomas","family":"Kohnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"1936_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","volume":"195","author":"JJ Chen","year":"2018","unstructured":"Chen\u00a0JJ, Flanagan\u00a0EP, Jitprapaikulsan\u00a0J et al (2018) Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol 195:8\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.020","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1936_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius\u00a0S, Ruprecht\u00a0K, Kleiter\u00a0I et al (2016) MOG-IgG in NMO and related disorders: a\u00a0multicenter study of 50\u00a0patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J\u00a0Neuroinflammation 13(1):280. https:\/\/doi.org\/10.1186\/s12974-016-0718-0","journal-title":"J Neuroinflammation"},{"key":"1936_CR3","doi-asserted-by":"publisher","unstructured":"Jurynczyk, M., Messina, S., Woodhall, M. R. et al (2017). Clinical presentation and prognosis in MOG-antibody disease: a\u00a0UK study. Brain: a\u00a0journal of neurology, 140(12), 3128\u20133138. https:\/\/doi.org\/10.1093\/brain\/awx276","DOI":"10.1093\/brain\/awx276"},{"issue":"1","key":"1936_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","volume":"13","author":"F Pache","year":"2016","unstructured":"Pache\u00a0F, Zimmermann\u00a0H, Mikolajczak\u00a0J et al (2016) MOG-IgG in NMO and related disorders: a\u00a0multicenter study of 50\u00a0patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J\u00a0Neuroinflammation 13(1):282. https:\/\/doi.org\/10.1186\/s12974-016-0720-6","journal-title":"J Neuroinflammation"},{"key":"1936_CR5","doi-asserted-by":"publisher","unstructured":"Ramanathan, S., Reddel, S. W., Henderson, A. et\u00a0al (2014). Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurology (R)\u00a0neuroimmunology & neuroinflammation, 1(4), e40. https:\/\/doi.org\/10.1212\/NXI.0000000000000040","DOI":"10.1212\/NXI.0000000000000040"},{"key":"1936_CR6","doi-asserted-by":"publisher","unstructured":"Ramanathan, S., Mohammad, S., Tantsis, E. et al (2018). Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. Journal of neurology, neurosurgery, and psychiatry, 89(2), 127\u2013137. https:\/\/doi.org\/10.1136\/jnnp-2017-316880","DOI":"10.1136\/jnnp-2017-316880"},{"key":"1936_CR7","doi-asserted-by":"publisher","unstructured":"Reindl, M., Waters, P. (2019). Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nature reviews. Neurology, 15(2), 89\u2013102. https:\/\/doi.org\/10.1038\/s41582-018-0112-x","DOI":"10.1038\/s41582-018-0112-x"},{"issue":"1","key":"1936_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","volume":"89","author":"A Cobo-Calvo","year":"2021","unstructured":"Cobo-Calvo\u00a0A, Ruiz\u00a0A, Rollot\u00a0F, Arrambide\u00a0G et al (2021) Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Ann Neurol 89(1):30\u201341. https:\/\/doi.org\/10.1002\/ana.25909","journal-title":"Ann Neurol"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-023-01936-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-023-01936-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-023-01936-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T11:14:45Z","timestamp":1707390885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-023-01936-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1936"],"URL":"https:\/\/doi.org\/10.1007\/s00347-023-01936-z","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"type":"print","value":"2731-720X"},{"type":"electronic","value":"2731-7218"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"24 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Kohnen macht folgende Angaben: Berater f\u00fcr Allergan, Bausch& Lomb, Geuder, Med Update, Santen, Staar, Thieme, Ziemer. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and participation on a Data Safety Monitoring Board or Advisory Board: Alcon\/Novartis, J&, LensGen, Oculentis, Oculus, Presbia, Schwind, Zeiss. Alcon\/Novartis, J&, LensGen, Oculentis, Oculus, Presbia, Schwind, Zeiss. Nothing in relation to this publication. J.\u00a0Bucur, K.P.\u00a0Kaiser, M.L.\u00a0Biller, T.\u00a0Jandewerth und N.\u00a0Kenikstul geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}